Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 21

1.

Prolonged TNFα primes fibroblast-like synoviocytes in a gene-specific manner by altering chromatin.

Sohn C, Lee A, Qiao Y, Loupasakis K, Ivashkiv LB, Kalliolias GD.

Arthritis Rheumatol. 2014 Sep 8. doi: 10.1002/art.38871. [Epub ahead of print]

PMID:
25199798
[PubMed - as supplied by publisher]
2.

Modulation of TNF-Induced Macrophage Polarization by Synovial Fibroblasts.

Donlin LT, Jayatilleke A, Giannopoulou EG, Kalliolias GD, Ivashkiv LB.

J Immunol. 2014 Sep 1;193(5):2373-83. doi: 10.4049/jimmunol.1400486. Epub 2014 Jul 23.

PMID:
25057003
[PubMed - in process]
3.

Kinase inhibitors: a new tool for the treatment of rheumatoid arthritis.

Chakravarty SD, Poulikakos PI, Ivashkiv LB, Salmon JE, Kalliolias GD.

Clin Immunol. 2013 Jul;148(1):66-78. doi: 10.1016/j.clim.2013.04.007. Epub 2013 Apr 17. Review.

PMID:
23651870
[PubMed - indexed for MEDLINE]
4.

iRHOM2 is a critical pathogenic mediator of inflammatory arthritis.

Issuree PD, Maretzky T, McIlwain DR, Monette S, Qing X, Lang PA, Swendeman SL, Park-Min KH, Binder N, Kalliolias GD, Yarilina A, Horiuchi K, Ivashkiv LB, Mak TW, Salmon JE, Blobel CP.

J Clin Invest. 2013 Feb 1;123(2):928-32. doi: 10.1172/JCI66168. Epub 2013 Jan 25.

PMID:
23348744
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Tumor necrosis factor α induces sustained signaling and a prolonged and unremitting inflammatory response in rheumatoid arthritis synovial fibroblasts.

Lee A, Qiao Y, Grigoriev G, Chen J, Park-Min KH, Park SH, Ivashkiv LB, Kalliolias GD.

Arthritis Rheum. 2013 Apr;65(4):928-38. doi: 10.1002/art.37853.

PMID:
23335080
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

The interferon signature and STAT1 expression in rheumatoid arthritis synovial fluid macrophages are induced by tumor necrosis factor α and counter-regulated by the synovial fluid microenvironment.

Gordon RA, Grigoriev G, Lee A, Kalliolias GD, Ivashkiv LB.

Arthritis Rheum. 2012 Oct;64(10):3119-28. doi: 10.1002/art.34544.

PMID:
22614743
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Type I interferons as biomarkers in autoimmune diseases.

Kalliolias GD, Kirou KA.

Biomark Med. 2012 Apr;6(2):137-40. doi: 10.2217/BMM.12.8. No abstract available.

PMID:
22448787
[PubMed - indexed for MEDLINE]
Free Article
8.

Suppression of TNF-α and IL-1 signaling identifies a mechanism of homeostatic regulation of macrophages by IL-27.

Kalliolias GD, Gordon RA, Ivashkiv LB.

J Immunol. 2010 Dec 1;185(11):7047-56. doi: 10.4049/jimmunol.1001290. Epub 2010 Oct 22.

PMID:
20971923
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

A new tool for detection of type I interferon activation in systemic lupus erythematosus.

Kirou KA, Kalliolias GD.

Arthritis Res Ther. 2010;12(4):138. doi: 10.1186/ar3114. Epub 2010 Aug 26.

PMID:
20815919
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Overview of the biology of type I interferons.

Kalliolias GD, Ivashkiv LB.

Arthritis Res Ther. 2010;12 Suppl 1:S1. doi: 10.1186/ar2881. Epub 2010 Apr 14.

PMID:
20392288
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Indirect inhibition of Toll-like receptor and type I interferon responses by ITAM-coupled receptors and integrins.

Wang L, Gordon RA, Huynh L, Su X, Park Min KH, Han J, Arthur JS, Kalliolias GD, Ivashkiv LB.

Immunity. 2010 Apr 23;32(4):518-30. doi: 10.1016/j.immuni.2010.03.014. Epub 2010 Apr 1.

PMID:
20362473
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Proliferative lesions and metalloproteinase activity in murine lupus nephritis mediated by type I interferons and macrophages.

Triantafyllopoulou A, Franzke CW, Seshan SV, Perino G, Kalliolias GD, Ramanujam M, van Rooijen N, Davidson A, Ivashkiv LB.

Proc Natl Acad Sci U S A. 2010 Feb 16;107(7):3012-7. doi: 10.1073/pnas.0914902107. Epub 2010 Jan 26.

PMID:
20133703
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Interleukin-27 inhibits human osteoclastogenesis by abrogating RANKL-mediated induction of nuclear factor of activated T cells c1 and suppressing proximal RANK signaling.

Kalliolias GD, Zhao B, Triantafyllopoulou A, Park-Min KH, Ivashkiv LB.

Arthritis Rheum. 2010 Feb;62(2):402-13. doi: 10.1002/art.27200.

PMID:
20112358
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Targeting cytokines in inflammatory diseases: focus on interleukin-1-mediated autoinflammation.

Kalliolias GD, Ivashkiv LB.

F1000 Biol Rep. 2009 Sep 8;1:70. doi: 10.3410/B1-70.

PMID:
20948617
[PubMed]
Free PMC Article
15.

Effect of epoetin alpha therapy on cognitive function in anaemic patients with solid tumours undergoing chemotherapy.

Iconomou G, Koutras A, Karaivazoglou K, Kalliolias GD, Assimakopoulos K, Argyriou AA, Ifanti A, Kalofonos HP.

Eur J Cancer Care (Engl). 2008 Nov;17(6):535-41. doi: 10.1111/j.1365-2354.2007.00857.x. Epub 2008 Aug 13.

PMID:
18707621
[PubMed - indexed for MEDLINE]
16.
17.

The future of the IL-1 receptor antagonist anakinra: from rheumatoid arthritis to adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis.

Kalliolias GD, Liossis SN.

Expert Opin Investig Drugs. 2008 Mar;17(3):349-59. doi: 10.1517/13543784.17.3.349 . Review.

PMID:
18321234
[PubMed - indexed for MEDLINE]
18.

Anakinra treatment in patients with adult-onset Still's disease is fast, effective, safe and steroid sparing: experience from an uncontrolled trial.

Kalliolias GD, Georgiou PE, Antonopoulos IA, Andonopoulos AP, Liossis SN.

Ann Rheum Dis. 2007 Jun;66(6):842-3. No abstract available.

PMID:
17513574
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Of temples and plane trees: the Hippocratic legacy as collective memory.

Sykiotis GP, Kalliolias GD, Terezis C, Papavassiliou AG.

Hormones (Athens). 2005 Jan-Mar;4(1):55-8. No abstract available.

PMID:
16574632
[PubMed - indexed for MEDLINE]
Free Article
20.

Hippocrates and genomic medicine.

Sykiotis GP, Kalliolias GD, Papavassiliou AG.

Arch Med Res. 2006 Jan;37(1):181-3. No abstract available.

PMID:
16314208
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk